Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent cause of liver disease in Western countries. The development of non-alcoholic steatohepatitis (NASH) and fibrosis identifies an at-risk group with increased risk of cardiovascular and liver-related deaths. The identification and management of this at-risk group remains a clinical challenge. AIM: To perform a systematic review of the established and emerging strategies for the diagnosis and staging of NAFLD. METHODS: Relevant research and review articles were identified by searching PubMed, MEDLINE and EMBASE. RESULTS: There has been a substantial development of non-invasive risk scores, biomarker panels and radiological modalities to identify at-risk patients with NAFLD without recourse to liver biopsy on a routine basis. These modalities and algorithms have improved significantly in their diagnosis and staging of fibrosis and NASH in patients with NAFLD, and will likely impact on the number of patients undergoing liver biopsy. CONCLUSIONS: Staging for NAFLD can now be performed by a combination of radiological and laboratory techniques, greatly reducing the requirement for invasive liver biopsy.

Original publication

DOI

10.1111/j.1365-2036.2010.04556.x

Type

Journal article

Journal

Aliment Pharmacol Ther

Publication Date

03/2011

Volume

33

Pages

525 - 540

Keywords

Biomarkers, Disease Progression, Fatty Liver, Hepatitis, Humans, Non-alcoholic Fatty Liver Disease, Risk Factors